Immix Biopharma, Inc. (IMMX) — Financial statements
Income statement, balance sheet, and cash flow for Immix Biopharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.36 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 16↑44.0% | 11↑29.3% | 9↑108.2% | 4↑3216.1% | 0.13 | |
| General & Administrative Expenses | 14↑20.3% | 11↑53.7% | 7↑84.1% | 4↑228.3% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 14↑20.3% | 11↑53.7% | 7↑84.1% | 4↑228.3% | 1 | |
| Other Expenses | -3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 27↑18.4% | 23↑40.5% | 16↑96.4% | 8↑507.9% | 1 | |
| Total Costs & Expenses | 27↑20.0% | 23↑40.5% | 16↑96.4% | 8↑507.9% | 1 | |
| Operating Results | ||||||
| Operating Income | -27↓20.0% | -23↓40.5% | -16↓96.4% | -8↓507.9% | -1 | |
| Depreciation & Amortization | 0.36↑215.9% | 0.12↑2010.2% | 0.01↑156.1% | 0.00↓13.5% | 0.00 | |
| EBITDA | -27↓19.0% | -23↓39.8% | -16↓96.4% | -8↑66.0% | -24 | |
| EBIT | -27↓20.0% | -23↓40.5% | -16↓96.4% | -8↑66.0% | -24 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.56↓45.4% | 1↑77.9% | 0.57↑115191.8% | -0.00↑99.7% | -0.18 | |
| Interest Income | 0.56↓45.4% | 1↑77.9% | 0.57 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓99.7% | 0.18 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 23 | |
| Other Income / Expenses | -2↓315.2% | 1↑77.9% | 0.57↑115191.8% | -0.00↑100.0% | -23 | |
| Income Before Tax | -29↓35.8% | -22↓39.1% | -16↓89.4% | -8↑66.3% | -24 | |
| Income Tax Expense | 0.04↓8.1% | 0.04↑55.4% | 0.03↑157.3% | 0.01↑70.8% | 0.01 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -29↓35.7% | -22↓39.1% | -16↓89.5% | -8↑66.2% | -24 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -29↓36.2% | -22↓40.1% | -15↓87.4% | -8↑66.2% | -24 | |
| Bottom-Line Net Income | -29↓36.2% | -22↓40.1% | -15↓87.4% | -8↑66.2% | -24 | |
| EPS (Basic) | -0.89↓17.1% | -0.76↑14.6% | -0.89↓50.8% | -0.59↑91.1% | -6.64 | |
| EPS (Diluted) | -0.89↓17.1% | -0.76↑14.6% | -0.89↓50.8% | -0.59↑91.1% | -6.64 | |
| Weighted Average Shares | 33↑16.5% | 28↑63.1% | 17↑24.9% | 14↑278.1% | 4 | |
| Weighted Average Diluted Shares | 33↑16.5% | 28↑63.1% | 17↑24.9% | 14↑278.1% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.